Skip to main content
Dennis Slamon, MD, Oncology, Santa Monica, CA, UCLA Medical Center-Santa Monica

DennisJosephSlamonMD

Oncology • Santa Monica, CA

Breast Cancer, Hematologic Oncology

UCLA School of Medicine

Join to view full profile

Dr. Slamon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Slamon's full profile

Already have an account?

  • Office

    2020 Santa Monica BoulevardSuite 580
    Santa Monica, CA 90404
    Phone+1 310-829-5471
    Fax+1 310-829-5471
  • Is this information wrong?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 1975 - 1979
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1975

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1976 - Present
  • CA State Medical License
    CA State Medical License 1979 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1988
  • Super Doctor SuperDoctors.com
  • Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor recept... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer 
    University of California, Costa Mesa, California - 5/17/2013
  • Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2â€) advanced breast cancer (ABC): Results from MO... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Targeted Therapy for Early Breast Cancer and Advances in PSMA PET Scans at ASCO
    Targeted Therapy for Early Breast Cancer and Advances in PSMA PET Scans at ASCOMay 22nd, 2023
  • UCLA Health Director of Cancer Services Shepherds Revolutionary Treatment Advances
    UCLA Health Director of Cancer Services Shepherds Revolutionary Treatment AdvancesApril 26th, 2023
  • Novartis Ribociclib Phase III NATALEE Trial Meets Primary Endpoint at Interim Analysis
    Novartis Ribociclib Phase III NATALEE Trial Meets Primary Endpoint at Interim AnalysisApril 24th, 2023
  • Join now to see all

Grant Support

  • Cru - Clinical Research Unit Shared ResourceNational Cancer Institute2009–2012
  • The Transcription Factor SLUG May Drive The Progression Of AKT And Her2/NeuNational Cancer Institute2010–2011
  • Signal Transduction In OncogenesisNational Cancer Institute1995–2006
  • Academic Training In Medical OncologyNational Cancer Institute1991–2005
  • Core--Tissue BankNational Cancer Institute2002
  • Her-2/Neu Alterations In Breast And Ovarian CancerNational Cancer Institute1995–2002
  • Phase I Study In Patients With Peritoneal Carcinomatosis Using Sch58500National Center For Research Resources1999–2001
  • Advances In Human Breast And Prostate CancerNational Cancer Institute2000
  • Phase I Study In Patients With Peritoneal CarcinomatosisNational Center For Research Resources1998
  • Clinical Cancer Research DevelopmentNational Cancer Institute1994–1996
  • Oncogenes In Physiologic And Pathologic StatesNational Cancer Institute1985–1996
  • Medical OncologyNational Cancer Institute1992–1995
  • Specialized Program Of Research Excellence/Breast CancerNational Cancer Institute1992–1994
  • A Program In Medical OncologyNational Cancer Institute1993
  • Academic Training In HematologyNational Institute Of Diabetes And Digestive And Kidney Diseases1992–1993
  • UCLA Clinical Cancer Research DevelopmentNational Cancer Institute1992–1993
  • Clinical Studies Of Biological Response ModifiersDivision Of Cancer Treatment1991–1993
  • Oncogenes In Physiologic &Pathological StatesNational Cancer Institute1987–1988

Hospital Affiliations

Dr. Dennis Slamon, Dr. Dennis Slamon, MD, Dr. D Slamon, Dr. Dennis Joseph Slamon